Share This Page
Drug Price Trends for NORG-ETHIN ESTRA
✉ Email this page to a colleague
Average Pharmacy Cost for NORG-ETHIN ESTRA
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| NORG-ETHIN ESTRA 0.25-0.035 MG | 68462-0309-29 | 0.11128 | EACH | 2024-12-18 |
| NORG-ETHIN ESTRA 0.25-0.035 MG | 68180-0840-73 | 0.11128 | EACH | 2024-12-18 |
| NORG-ETHIN ESTRA 0.25-0.035 MG | 68462-0309-84 | 0.11128 | EACH | 2024-12-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Norgestimate and Ethinyl Estradiol
Introduction
Norgestimate and ethinyl estradiol, a combination oral contraceptive, is widely used for birth control, acne treatment, and managing abnormal uterine bleeding. Here, we will delve into the market analysis, price projections, and other relevant factors influencing this medication.
Market Size and Growth
The global contraceptive drugs market, which includes norgestimate and ethinyl estradiol, is significant and growing. As of 2023, the global contraceptive drugs market was valued at USD 18.57 billion and is projected to reach USD 37.22 billion by 2032, with a Compound Annual Growth Rate (CAGR) of 8.2% from 2024 to 2032[4].
Segment Dominance
The oral segment, which includes norgestimate and ethinyl estradiol, accounts for the highest market share. This dominance is driven by the higher adoption of oral drugs due to their ease of administration, clinical benefits, and widespread availability in pharmacies and public hospitals[4].
Key Drivers
Several factors are driving the growth of the contraceptive drugs market, including:
- Increasing Awareness: Public programs aimed at creating awareness about contraceptive options are boosting demand.
- Growing Insurance Coverage: Expanded insurance coverage is making these medications more accessible.
- OTC Availability: The introduction of over-the-counter (OTC) contraceptive products is also a significant driver[4].
Market Players
Major pharmaceutical companies such as Johnson & Johnson Services, Inc., AbbVie Inc., and Bayer AG are key players in the contraceptive drugs market. These companies influence pricing and market dynamics through their product offerings and marketing strategies[4].
Pricing and Cost
The cost of norgestimate and ethinyl estradiol tablets can vary depending on the pharmacy and the specific formulation. Here are some general price ranges:
- A supply of 28 tablets of the 35 mcg-0.25 mg formulation can cost around $18 to $29.95, depending on the pharmacy and any discounts applied[2].
- For triphasic formulations, prices can range from $29.95 to $41.87 for a supply of 28 to 84 tablets[2].
Patient Assistance Programs
While there are no specific patient assistance programs listed for norgestimate and ethinyl estradiol, patients may benefit from general copay cards and discount programs offered by pharmacies and pharmaceutical companies. Healthcare providers can also provide information on available programs in their area[2].
Regional Market
North America dominated the contraceptive drugs market in 2023, with a market size valued at USD 7.27 billion. This region is expected to continue its strong presence in the market due to high adoption rates and favorable healthcare policies[4].
Clinical and Pharmacokinetic Considerations
Understanding the pharmacokinetics of norgestimate and ethinyl estradiol is crucial for both patients and healthcare providers. These drugs are rapidly absorbed, with peak serum concentrations of norelgestromin (NGMN) and ethinyl estradiol (EE) generally reached within 2 hours of administration. Steady-state concentrations are achieved by Day 7 for EE and Day 21 for NGMN and norgestrel (NG)[1].
Side Effects and Contraindications
It is important to note that oral contraceptives, including norgestimate and ethinyl estradiol, come with certain risks and contraindications. For example, cigarette smoking significantly increases the risk of serious cardiovascular side effects, particularly in women over 35 years old[1].
Future Outlook
Given the steady growth in the contraceptive drugs market and the increasing demand for oral contraceptives, it is likely that norgestimate and ethinyl estradiol will continue to be a significant part of this market. The introduction of new products and generic equivalents, such as Lupin’s Drospirenone tablets approved in November 2022, will also influence market dynamics and pricing[4].
Key Takeaways
- Market Growth: The global contraceptive drugs market is projected to grow significantly, driven by the oral segment.
- Pricing: The cost of norgestimate and ethinyl estradiol tablets varies but is generally affordable with discounts and patient assistance programs.
- Regional Dominance: North America leads the market due to high adoption rates and favorable healthcare policies.
- Clinical Considerations: Understanding the pharmacokinetics and potential side effects is crucial for effective use.
- Future Outlook: The market is expected to continue growing, influenced by new product approvals and changing healthcare policies.
FAQs
Q: What is the typical cost of norgestimate and ethinyl estradiol tablets? A: The cost can range from $18 to $29.95 for a supply of 28 tablets, depending on the pharmacy and any discounts applied[2].
Q: Are there patient assistance programs available for norgestimate and ethinyl estradiol? A: While there are no specific programs listed for this medication, patients may benefit from general copay cards and discount programs offered by pharmacies and pharmaceutical companies[2].
Q: What are the key drivers of the contraceptive drugs market? A: Increasing awareness through public programs, growing insurance coverage, and the introduction of OTC contraceptive products are key drivers[4].
Q: Which region dominates the contraceptive drugs market? A: North America dominated the market in 2023, with a market size valued at USD 7.27 billion[4].
Q: What are the pharmacokinetic characteristics of norgestimate and ethinyl estradiol? A: These drugs are rapidly absorbed, with peak serum concentrations reached within 2 hours, and steady-state concentrations achieved by Day 7 for EE and Day 21 for NGMN and NG[1].
Sources
- DailyMed: Norgestimate and Ethinyl Estradiol Tablets USP, 0.25 mg/0.035 mg.
- Drugs.com: Ethinyl estradiol/norgestimate Prices, Coupons, Copay Cards & Patient Assistance.
- ASPE: Medicare Drug Price Negotiation Program: Understanding the Selected Drugs.
- Fortune Business Insights: Contraceptive Drugs Market Size, Share | Global Report, 2032.
More… ↓
